Anavex Life Sciences Corp (AVXL)

[falconer66a]

Missling, prophylaxis, and the Anavex trifecta.

...the Dr. saying "it's important to be aware of this prevention potential"--the only disease mentioned was Alzheimer's-as being a preventative for (that's what was being used in the pre-clinical)--as far as being effective on humans (after being found to be effective for animals)...

Lots of things involved.

Dr. Missling’s specific telling of the “prevention potential” (prophylaxis) of Alzheimer’s by blarcamesine was not an incidental offhand remark. I may have been one of the first here in this message board, some good time ago, to project that if blarcamesine is able to stop or reverse the progression of Alzheimer’s (as a treatment), it almost surely would also prevent it in the first place (prophylaxis).

Is it mere happenstance that at least three people have publicly offered this conjecture? Some time ago (and in subsequent postings) I’ve laid out the biology of this application. Now (once again, but even more decisively) Dr. Christopher Missling, Anavex CEO makes a public utterance on the subject. Then, earlier, was the statement by Dr. Randi Hagerman, a neurology disease researcher, familiar with blarcamesine in human clinical trials she oversees, that she desired to take blarcamesine herself, to ward off geriatric CNS diseases.

No mystery on this. All three of us know neurological biochemistry and physiology sufficiently to understand the potential. Others do, too.

Now, Dr. Missling’s recent statement seems to imply that he and his compatriots may be familiar with animal trials that substantiate the conjecture. Very easy to test; I’m rather certain Anavex has done this. Simply, dose transgenic mice with Alzheimer’s genes with blarcamesine; compare their cognition to the same mice without blarcamesine dosings. I doubt that Missling would have made his claim of prophylaxis without internal murine trials that show prophylaxis.

Lastly, I’ve previously contended that all sorts of other favorable therapeutic outcomes will be noted and assessed in people taking blarcamesine, not just symptomatic relief from Parkinson’s or Alzheimer’s. More favorable, healthful sleep. Improved cardiovascular health. Reduced onset or development of cancers. Etc. Just the improved sleep factor would be enough to prompt the use of blarcamesine as a soporific. Sleep deprivation is a major human health condition. Treating it successfully with a safe drug like blarcamesine will be extremely important; may happen after the effects are noted in people taking the drug for CNS diseases.

The wide, other yet un-recognized health benefits that blarcamesine will ultimately provide need yet to be discovered. I’m certain that Dr. Missling, from private internal research on murines (lab rodents) knows of a good number. The Anavex trifecta of just Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s, is just the first regulatory wager the company will win. Bigger ones after 2022.

After that... ....we’ll be watching. Already, lots of supportive preclinical data.

[And yes, eventual veterinary uses. Potentially big. A future topic.]